Study links ibuprofen CVD risks
This article was originally published in The Tan Sheet
Executive Summary
Ibuprofen, among other nonselective nonsteroidal anti-inflammatory drugs, might increase the risk of cardiovascular disease events in certain patients, according to research in the August issue of Arthritis Care & Research. Working with consumers at least 80 years old who take NSAIDs to relieve arthritis symptoms, the researchers from Brigham and Women's Hospital in Boston find "several patient characteristics identify important subgroups that may be at an increased risk when using specific agents," according to the study. The researchers link ibuprofen use with increased CVD event risk in patients with histories of hypertension, prior myocardial infarction, rheumatoid arthritis and chronic renal diseaseYou may also be interested in...
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?
Sage Still Sees Approval Path After Depression Drug Fails In Phase III Trial
Sage Therapeutics points to patient compliance and selection as factors in its failed trial of SAGE-217. The company sees positive implications in the data as it waits for other SAGE-217 studies.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: